Summary

Africa Pharmaceutical Market Size & Trends

The Africa pharmaceutical market size was estimated at USD 27.65 billion in 2024 and is projected to reach USD 36.96 billion by 2033, growing at a CAGR of 3.3% from 2025 to 2033. Due to the increasing prevalence of both communicable and non-communicable diseases, pharmaceutical demand is expanding rapidly across the continent. Infectious diseases such as malaria, tuberculosis, and HIV/AIDS remain persistent health challenges requiring sustained drug supply. At the same time, lifestyle-related illnesses like diabetes, hypertension, and cardiovascular disorders are on the rise, driven by urbanization and changing dietary habits. This dual disease burden is creating continuous demand for a diverse range of treatments, from affordable generics to advanced biologics. Expanding access to diagnostics and preventive healthcare is also contributing to higher medicine consumption. Collectively, these factors are reinforcing the pharmaceutical sector’s role as a critical pillar of healthcare systems.

The increasing investments in healthcare infrastructure and medical service delivery are accelerating the growth of the pharmaceutical industry. Governments and private sector players are modernizing hospitals, expanding community clinics, and integrating advanced technology into healthcare systems. Public-private partnerships are strengthening medicine distribution channels, improving access in rural and underserved regions. Local manufacturing initiatives in major economies are enhancing self-reliance and reducing dependence on imported drugs.

Donor-funded programs are ensuring the supply of essential medicines for high-burden diseases. For instance, in June 2025, the International Centre for Trade Transparency reported that a leading global logistics firm committed approximately USD 540 billion over five years to enhance healthcare infrastructure across Africa and the Middle East. This included advanced logistics hubs in South Africa, Egypt, Kenya, Dubai, and Saudi Arabia for high-value, time-sensitive shipments such as vaccines, stem cells, and cryogenic materials. Part of a USD 8.64 billion global initiative, this investment strengthens cold-chain networks, warehousing, and supply-chain traceability to meet growing healthcare needs.

The increasing emphasis on regulatory harmonization and continental market integration is opening up new opportunities for industry expansion. Initiatives such as the African Medicines Regulatory Harmonization program and the African Medicines Agency are standardizing approval processes across member states. This creates a more predictable regulatory environment, encouraging local and foreign investment in the sector. Smaller markets benefit from faster access to innovative medicines, while pharmaceutical companies can leverage streamlined cross-border trade.

For instance, in July 2025, Reuters reported that eight African countries took part in a joint regulatory assessment, enabling faster access to a new malaria treatment for infants under 4.5 kg. This collaborative approach shortened approval timelines across the participating nations, improving treatment availability in high-burden malaria regions, with the sweet cherry–flavored formulation dissolving easily in liquids such as breast milk to aid caregivers. Pooled procurement strategies are helping lower drug prices and improve affordability, while enhanced compliance with international quality standards is boosting confidence in locally produced medicines, strengthening Africa’s position as a competitive pharmaceutical hub.

Africa Pharmaceutical Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Africa pharmaceutical market report based on molecule type, product, type, disease, route of administration, formulation, age group, end-user, and country:

• Molecule Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Biologics & Biosimilars (Large Molecules)
• Conventional Drugs (Small Molecules)
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Branded
• Generic
• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Prescription
• OTC
• Disease Outlook (Revenue, USD Billion, 2021 - 2033)
• Cardiovascular Diseases
• Cancer
• Diabetes
• Infectious Diseases
• Neurological Disorders
• Respiratory Diseases
• Autoimmune Diseases
• Mental Health Disorders
• Gastrointestinal Disorders
• Women’s Health Diseases
• Genetic And Rare Genetic Diseases
• Dermatological Conditions
• Obesity
• Renal Diseases
• Liver Conditions
• Hematological Disorders
• Eye Conditions
• Infertility Conditions
• Endocrine Disorders
• Allergies
• Others
• Route Of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Topical
• Parenteral
o Intravenous
o Intramuscular
• Inhalations
• Others
• Formulation Outlook (Revenue, USD Billion, 2021 - 2033)
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
• Age Group Outlook (Revenue, USD Billion, 2021 - 2033)
• Children & Adolescents
• Adults
• Geriatric
• End-user Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Clinics
• Others
• Country Outlook (Revenue, USD Billion, 2021 - 2033)
• Botswana
• Namibia
• Zimbabwe
• Zambia
• Tanzania
• Rwanda
• Ghana
• Nigeria
• South Africa
• Angola
• Mozambique
• Cameroon
• Senegal
• Ivory Coast

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule Type
1.2.2. Product
1.2.3. Type
1.2.4. Disease
1.2.5. Route of Administration
1.2.6. Formulation
1.2.7. Age Group
1.2.8. End User
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Africa Pharmaceutical Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Africa Pharmaceutical Market: Molecule Type Business Analysis
4.1. Molecule Type Market Share, 2024 & 2033
4.2. Molecule Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Billion)
4.4. Biologics & Biosimilars (Large Molecules)
4.4.1. Biologics & Biosimilars (Large Molecules) Market, 2021 - 2033 (USD Billion)
4.4.1.1. Monoclonal Antibodies
4.4.1.1.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Billion)
4.4.1.2. Vaccines
4.4.1.2.1. Vaccines Market, 2021 - 2033 (USD Billion)
4.4.1.3. Cell & Gene Therapy
4.4.1.3.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Billion)
4.4.1.4. Others
4.4.1.4.1. Others Biologics & Biosimilars Market, 2021 - 2033 (USD Billion)
4.5. Conventional Drugs (Small Molecules)
4.5.1. Conventional Drugs (Small Molecules) Market, 2021 - 2033 (USD Billion)
Chapter 5. Africa Pharmaceutical Market: Product Business Analysis
5.1. Product Market Share, 2024 & 2033
5.2. Product Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Billion)
5.4. Branded
5.4.1. Branded Market, 2021 - 2033 (USD Billion)
5.5. Generic
5.5.1. Generic Market, 2021 - 2033 (USD Billion)
Chapter 6. Africa Pharmaceutical Market: Type Business Analysis
6.1. Type Market Share, 2024 & 2033
6.2. Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
6.4. Prescription
6.4.1. Prescription Market, 2021 - 2033 (USD Billion)
6.5. OTC
6.5.1. OTC Market, 2021 - 2033 (USD Billion)
Chapter 7. Africa Pharmaceutical Market: Disease Business Analysis
7.1. Disease Market Share, 2024 & 2033
7.2. Disease Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Billion)
7.4. Cardiovascular diseases
7.4.1. Cardiovascular diseases Market, 2021 - 2033 (USD Billion)
7.5. Cancer
7.5.1. Cancer Market, 2021 - 2033 (USD Billion)
7.6. Diabetes
7.6.1. Diabetes Market, 2021 - 2033 (USD Billion)
7.7. Infectious diseases
7.7.1. Infectious diseases Market, 2021 - 2033 (USD Billion)
7.8. Neurological disorders
7.8.1. Neurological disorders Market, 2021 - 2033 (USD Billion)
7.9. Respiratory diseases
7.9.1. Respiratory diseases Market, 2021 - 2033 (USD Billion)
7.10. Autoimmune diseases
7.10.1. Autoimmune diseases Market, 2021 - 2033 (USD Billion)
7.11. Mental health disorders
7.11.1. Mental health disorders Market, 2021 - 2033 (USD Billion)
7.12. Gastrointestinal disorders
7.12.1. Gastrointestinal disorders Market, 2021 - 2033 (USD Billion)
7.13. Women’s health diseases
7.13.1. Women’s health diseases Market, 2021 - 2033 (USD Billion)
7.14. Genetic and rare genetic diseases
7.14.1. Genetic and rare genetic diseases Market, 2021 - 2033 (USD Billion)
7.15. Dermatological conditions
7.15.1. Dermatological conditions Market, 2021 - 2033 (USD Billion)
7.16. Obesity
7.16.1. Obesity Market, 2021 - 2033 (USD Billion)
7.17. Renal diseases
7.17.1. Renal diseases Market, 2021 - 2033 (USD Billion)
7.18. Liver conditions
7.18.1. Liver conditions Market, 2021 - 2033 (USD Billion)
7.19. Hematological disorders
7.19.1. Hematological disorders Market, 2021 - 2033 (USD Billion)
7.20. Eye conditions
7.20.1. Eye conditions Market, 2021 - 2033 (USD Billion)
7.21. Infertility conditions
7.21.1. Infertility conditions Market, 2021 - 2033 (USD Billion)
7.22. Endocrine disorders
7.22.1. Endocrine disorders Market, 2021 - 2033 (USD Billion)
7.23. Allergies
7.23.1. Allergies Market, 2021 - 2033 (USD Billion)
7.24. Others
7.24.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 8. Africa Pharmaceutical Market: Route of Administration Business Analysis
8.1. Route of Administration Market Share, 2024 & 2033
8.2. Route of Administration Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
8.4. Oral
8.4.1. Oral Market, 2021 - 2033 (USD Billion)
8.5. Topical
8.5.1. Topical Market, 2021 - 2033 (USD Billion)
8.6. Parenteral
8.6.1. Parenteral Market, 2021 - 2033 (USD Billion)
8.6.2. Intravenous
8.6.2.1. Intravenous Market, 2021 - 2033 (USD Billion)
8.6.3. Intramuscular
8.6.3.1. Intramuscular Market, 2021 - 2033 (USD Billion)
8.7. Inhalations
8.7.1. Inhalations Market, 2021 - 2033 (USD Billion)
8.8. Other
8.8.1. Other Market, 2021 - 2033 (USD Billion)
Chapter 9. Africa Pharmaceutical Market: Formulation Business Analysis
9.1. Formulation Market Share, 2024 & 2033
9.2. Formulation Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Billion)
9.4. Tablets
9.4.1. Tablets Market, 2021 - 2033 (USD Billion)
9.5. Capsules
9.5.1. Capsules Market, 2021 - 2033 (USD Billion)
9.6. Injectable
9.6.1. Injectable Market, 2021 - 2033 (USD Billion)
9.7. Sprays
9.7.1. Sprays Market, 2021 - 2033 (USD Billion)
9.8. Suspensions
9.8.1. Suspensions Market, 2021 - 2033 (USD Billion)
9.9. Powders
9.9.1. Powders Market, 2021 - 2033 (USD Billion)
9.10. Other Formulations
9.10.1. Other Formulations Market, 2021 - 2033 (USD Billion)
Chapter 10. Africa Pharmaceutical Market: Age Group Business Analysis
10.1. Age Group Market Share, 2024 & 2033
10.2. Age Group Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Billion)
10.4. Children & Adolescents
10.4.1. Children & Adolescents Market, 2021 - 2033 (USD Billion)
10.5. Adults
10.5.1. Adults Market, 2021 - 2033 (USD Billion)
10.6. Geriatric
10.6.1. Geriatric Market, 2021 - 2033 (USD Billion)
Chapter 11. Africa Pharmaceutical Market: End User Business Analysis
11.1. End User Share, 2024 & 2033
11.2. End User Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Billion)
11.4. Hospitals
11.4.1. Hospitals Market, 2021 - 2033 (USD Billion)
11.5. Clinics
11.5.1. Clinics Market, 2021 - 2033 (USD Billion)
11.6. Others
11.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 12. Africa Pharmaceutical Market: Countries Estimates & Trend Analysis
12.1. Country Market Share Analysis, 2024 & 2033
12.2. Country Market Dashboard
12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
12.3.1. Botswana
12.3.1.1. Key Country Dynamics
12.3.1.2. Route of Administration Disease Prevalence
12.3.1.3. Regulatory Framework
12.3.1.4. Reimbursement Framework
12.3.1.5. Botswana Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.2. Namibia
12.3.2.1. Key Country Dynamics
12.3.2.2. Route of Administration Disease Prevalence
12.3.2.3. Regulatory Framework
12.3.2.4. Reimbursement Framework
12.3.2.5. Namibia Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.3. Zimbabwe
12.3.3.1. Key Country Dynamics
12.3.3.2. Route of Administration Disease Prevalence
12.3.3.3. Regulatory Framework
12.3.3.4. Reimbursement Framework
12.3.3.5. Zimbabwe Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.4. Zambia
12.3.4.1. Key Country Dynamics
12.3.4.2. Route of Administration Disease Prevalence
12.3.4.3. Regulatory Framework
12.3.4.4. Reimbursement Framework
12.3.4.5. Zambia Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.5. Tanzania
12.3.5.1. Key Country Dynamics
12.3.5.2. Route of Administration Disease Prevalence
12.3.5.3. Regulatory Framework
12.3.5.4. Reimbursement Framework
12.3.5.5. Tanzania Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.6. Rwanda
12.3.6.1. Key Country Dynamics
12.3.6.2. Route of Administration Disease Prevalence
12.3.6.3. Regulatory Framework
12.3.6.4. Reimbursement Framework
12.3.6.5. Rwanda Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.7. Ghana
12.3.7.1. Key Country Dynamics
12.3.7.2. Route of Administration Disease Prevalence
12.3.7.3. Regulatory Framework
12.3.7.4. Reimbursement Framework
12.3.7.5. Ghana Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.8. Nigeria
12.3.8.1. Key Country Dynamics
12.3.8.2. Route of Administration Disease Prevalence
12.3.8.3. Regulatory Framework
12.3.8.4. Reimbursement Framework
12.3.8.5. Nigeria Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.9. South Africa
12.3.9.1. Key Country Dynamics
12.3.9.2. Route of Administration Disease Prevalence
12.3.9.3. Regulatory Framework
12.3.9.4. Reimbursement Framework
12.3.9.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.10. Angola
12.3.10.1. Key Country Dynamics
12.3.10.2. Route of Administration Disease Prevalence
12.3.10.3. Regulatory Framework
12.3.10.4. Reimbursement Framework
12.3.10.5. Angola Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.11. Mozambique
12.3.11.1. Key Country Dynamics
12.3.11.2. Route of Administration Disease Prevalence
12.3.11.3. Regulatory Framework
12.3.11.4. Reimbursement Framework
12.3.11.5. Mozambique Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.12. Cameroon
12.3.12.1. Key Country Dynamics
12.3.12.2. Route of Administration Disease Prevalence
12.3.12.3. Regulatory Framework
12.3.12.4. Reimbursement Framework
12.3.12.5. Cameroon Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.13. Senegal
12.3.13.1. Key Country Dynamics
12.3.13.2. Route of Administration Disease Prevalence
12.3.13.3. Regulatory Framework
12.3.13.4. Reimbursement Framework
12.3.13.5. Senegal Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.14. Ivory Coast
12.3.14.1. Key Country Dynamics
12.3.14.2. Route of Administration Disease Prevalence
12.3.14.3. Regulatory Framework
12.3.14.4. Reimbursement Framework
12.3.14.5. Ivory Coast Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.3.15. Rest of Africa
12.3.15.1. Key Country Dynamics
12.3.15.2. Route of Administration Disease Prevalence
12.3.15.3. Regulatory Framework
12.3.15.4. Reimbursement Framework
12.3.15.5. Ivory Coast Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 13. Competitive Landscape
13.1. Participant Overview
13.2. Company Market Position Analysis
13.3. Company Categorization
13.4. Strategy Mapping
13.5. Company Profiles/Listing
13.5.1. Abbott Laboratories
13.5.1.1. Overview
13.5.1.2. Financial Performance
13.5.1.3. Product Benchmarking
13.5.1.4. Strategic Initiatives
13.5.2. AbbVie
13.5.2.1. Overview
13.5.2.2. Financial Performance
13.5.2.3. Product Benchmarking
13.5.2.4. Strategic Initiatives
13.5.3. Alfasigma
13.5.3.1. Overview
13.5.3.2. Financial Performance
13.5.3.3. Product Benchmarking
13.5.3.4. Strategic Initiatives
13.5.4. Aspen
13.5.4.1. Overview
13.5.4.2. Financial Performance
13.5.4.3. Product Benchmarking
13.5.4.4. Strategic Initiatives
13.5.5. Aurobindo Pharma
13.5.5.1. Overview
13.5.5.2. Financial Performance
13.5.5.3. Product Benchmarking
13.5.5.4. Strategic Initiatives
13.5.6. AstraZeneca
13.5.6.1. Overview
13.5.6.2. Financial Performance
13.5.6.3. Product Benchmarking
13.5.6.4. Strategic Initiatives
13.5.7. Bristol Myers Squibb
13.5.7.1. Overview
13.5.7.2. Financial Performance
13.5.7.3. Product Benchmarking
13.5.7.4. Strategic Initiatives
13.5.8. BGM
13.5.8.1. Overview
13.5.8.2. Financial Performance
13.5.8.3. Product Benchmarking
13.5.8.4. Strategic Initiatives
13.5.9. Cipla
13.5.9.1. Overview
13.5.9.2. Financial Performance
13.5.9.3. Product Benchmarking
13.5.9.4. Strategic Initiatives
13.5.10. Sun Pharma
13.5.10.1. Overview
13.5.10.2. Financial Performance
13.5.10.3. Product Benchmarking
13.5.10.4. Strategic Initiatives
13.5.11. BAYER
13.5.11.1. Overview
13.5.11.2. Financial Performance
13.5.11.3. Product Benchmarking
13.5.11.4. Strategic Initiatives